Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatme
Leading dermatologists discuss the innovations shaping 5 chronic skin diseases—psoriasis, atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa—and share the challenges and
An alliance between Spanish drugmaker Almirall and digital health company Happify has yielded its first fruit, with the launch of their Claro app designed to reduce anxiety and improve well
Roivant group company Dermavant has made the transition to a commercial-stage company after getting FDA approval for Vtama, a drug for psoriasis that it claims could be a game-changer in th
The FDA has delivered a blow to UCB's late-stage pipeline, after saying it is unable to approve its latecomer IL-17 inhibitor bimekizumab for moderate-to-severe plaque psoriasis.
People with psoriasis who used an app developed by digital health company Happify reported reduced anxiety and improvements in mental wellbeing in a real-world study involving more than two
Boehringer Ingelheim says it may have found the first therapy for diabetic macular ischaemia (DMI), a common and irreversible complication of the eye in people with diabet
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.